摘要
目的观察噻托溴铵对稳定期支气管扩张患者的临床疗效。方法将22例稳定期支气管扩张患者,予以噻托溴铵粉吸入剂18μg每日1次吸入治疗。于研究第1天、第28天检测1s用力呼气量(FEV1)、FEV1占预计值的百分比[FEV1(%)]、用力呼气量(FVC)、FEV1/FVC等指标及记录症状评分表,记录BODE指数。结果 22例患者使用噻托溴铵1月后FEV1%与使用前对照有所改善,但无统计学意义(t=-1.857,P>0.05);症状评分用药后1月与用药前比较降低,具有统计学意义(t=7.091,P<0.001);BODE指数用药后1月较用药前降低(t=2.982,P<0.05)。结论长期规律使用噻托溴铵粉吸入剂,能改善支气管扩张患者的临床症状,改善BODE指数,从而改善患者的运动耐量及生活质量。
Objective To observe the therapeutic effect of tiotropium bromide powder inhalation on stable bronchiectasis. Methods Twenty-two patients with stable bronchiectasis received inhalation of totropium bromide powder at the daily dose of 18 μg, and on days 1 and 28, the patients were examined for forced expiratory volume in one second （FEVl）, predicted value [FEVl （%）], forced expiratory volume （FEV）, and FEVl/FVC. The symptom score and BODE index were also recorded. Results After 1 month of inhalation therapy, the FEV1% of the patients showed a moderate increase but the increment was not statistically significant （t=-1.875, P0.05）; the symptom score and BODE index decreased significantly after the therapy （t= 7.091, P0.001; t=2.982, P0.05）. Conclusion Long-term inhalation of tiotropium bromide powder can improve the clinical symptoms and BODE index and enhance the exercise tolerance and quality of life of the patients with bronchiectasis.
出处
《南方医科大学学报》
CAS
CSCD
北大核心
2010年第5期1072-1074,共3页
Journal of Southern Medical University
基金
中华医学会慢性呼吸道专项资助项目(0802046012)
作者简介
李小玲（1979-），女，硕士研究生（现工作于江西省萍乡市人民医院呼吸内科），E-mail：myxiao2000@126．com
通迅作者：蔡绍曦，电话020-61641571，E-mail：hxkc@fimmu．com
